HomeNewsBusinessBudgetEconomic Survey 2023: No measure sufficient to counter COVID-19 like shock, says government

Economic Survey 2023: No measure sufficient to counter COVID-19 like shock, says government

Economic Survey 2023: The report, however, has also underlined that the health infrastructure has improved dramatically since the pandemic began in 2020

January 31, 2023 / 15:58 IST
Story continues below Advertisement
The Economic Survey 2023 noted that by January 6 this year, more than 220 crore vaccine doses were administered which included nearly 22 crore booster doses. (Representative image)
The Economic Survey 2023 noted that by January 6 this year, more than 220 crore vaccine doses were administered which included nearly 22 crore booster doses. (Representative image)

In what can be seen as the first acceptance of the failure on the part of the government to provide adequate healthcare service during the COVID-19 pandemic, the Economic Survey report 2023 has said that “no set of measures is sufficient to counter any instantaneous shock like the pandemic."

This, said the report tabled by Union finance minister Nirmala Sitharaman in the Rajya Sabha on January 31, was because the measures are designed with the assumption of ‘ceteris paribus’, meaning everything else remains the same.

Story continues below Advertisement

"But the major difference is that we are operating in a new normal, and hence towards the end, it is all about better management of the crisis and planning ahead,” it added. “Thus, the strong inventory India has built over the last few years will improve the country’s overall health infrastructure and governance system”.

ECONOMIC SURVEY 2023: Catch all the updates here

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show